EXPRESS: Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus.

This trial evaluated the effects of insulin aspart (IAsp) combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus (T2DM).Newly diagnosed T2DM patients (n = 96) were randomly divided into the control group and study group, 48 cases in each group, and treated with insulin detemir + metformin or insulin detemir + metformin + IAsp, respectively. Clinical effect was assessed, and blood glucose, body mass index (BMI), fasting insulin (FINS), insulin dosage, and blood glucose standard time were recorded. The insulin resistance index (homeostasis model assessment of insulin resistance) and insulin function index (homeostasis model assessment-β) were calculated. Adverse reactions were recorded, and quality of life and sleep quality were assessed.The total effective rate of the study group was 95.83%, which was higher than that of the control group 79.17%. The study group had lower blood glucose, BMI, and FINS, less insulin dosage, and shorter blood glucose standard time. Moreover, the study group had lower insulin resistance index and higher insulin function index, as well as better quality of life and sleep quality. The incidence of adverse reactions exhibited no difference between the two groups.Insulin detemir + metformin + IAsp is effective in the treatment of T2DM, which can effectively improve insulin function and blood glucose index, reduce BMI and insulin dosage without increasing adverse reactions, and improve quality of life and sleep quality.